And then potentially destroy Orion’s shareholder value in the process. As an Orion shareholder (I don’t own Faron), I do not support such a scenario at all. Deals can be made for interesting drug candidates, if there is potential. On the other hand, if Faron’s performance continues at this level, those assets could be acquired cheaply at some point—if there would even be any sense in that.
And if Faron stays afloat, those who believe in it can certainly continue funding it as an independent company. Drug development is arduous and risky; I trust Orion’s experience in this.